Croda Obtains EXCiPACT Certification for Mevisa Site - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Croda Obtains EXCiPACT Certification for Mevisa Site

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 8

Croda, an excipients supplier, announced that it has obtained EXCiPACT certification for its excipients manufacturing site at Mevisa, Spain.

This certification comes less than six months after Mevisa’s sister site at Rawcliffe Bridge in the UK achieved the same quality accreditation. With this pair of certifications, Croda is now able to offer pharmaceutical customers the benefits of the EXCiPACT scheme over a range of products from two separate manufacturing facilities.

The diverse excipient offering now covered by the certification of these two sites includes industry benchmark ingredients such as Span and Tween surfactants. Croda Mevisa and Rawcliffe Bridge are also home to more recent technologies such as the company’s Crodamol ISIS, a 100% naturally derived emollient ester with a novel method of action. This product works in synergy with the skin’s natural lipid barrier to help reduce transepidermal water loss to maintain an optimum level of skin hydration.

EXCiPACT is a voluntary scheme that reduces the audit burden in the pharmaceutical industry by providing independent third-party certification of manufacturers, suppliers, and distributors of excipients.

Croda is now continuing its global program to gain accreditation at all of its sites that supply pharmaceutical excipients.

Source: Croda

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here